

03rd March 2022

To
Department of Corporate Services,
BSE-Limited
PJ Towers, Dalal Street,
Fort, Mumbai – 400 001
Scrip Code: **BSE - 524500**

To
Corporate Listing Department
National Stock Exchange of India Ltd
Exchange Plaza, Plot No C-1, G Block,
BKC, Bandra (E)- Mumbai 400 051
Scrip Code: **NSE - KILITCH**

Dear Sir/ Madam,

Sub: Disclosure pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015 – Expansion of Manufacturing Facility at Khopoli.

Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 we wish to inform you that our company has purchased a land, admeasuring approximately 15 Acres, at Village Maldev, Taluka: Pen, on Pen- Khopoli Highway to establish a green field pharma complex. Kilitch has been one of the prominent manufacturer for Injectables from more than 30 years. The time is ripe to get into the league of Biotech products to spur the growth. We plan to setup 4-6 manufacturing units in different therapeutics categories to cater to the growing demands Nationally and Internationally.

All these manufacturing units will be built in line with our growth potential in Export Market. The project envisaged is futuristic and shall have maximum recognition of the world's leading regulatory authorities.

The above is for information and dissemination to the public at large.

Thanking you

Yours faithfully

For Kilitch Drugs (India) Limited


Mukund Mehta
Managing Director
DIN: 00147876

